These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Systematic Review and Meta-Analysis: Early Treatment Responses of Selective Serotonin Reuptake Inhibitors and Clomipramine in Pediatric Obsessive-Compulsive Disorder. Varigonda AL; Jakubovski E; Bloch MH J Am Acad Child Adolesc Psychiatry; 2016 Oct; 55(10):851-859.e2. PubMed ID: 27663940 [TBL] [Abstract][Full Text] [Related]
9. Neuropsychiatry of obsessive-compulsive disorder in children and adolescents. March JS; Leonard HL; Swedo SE Compr Ther; 1995 Sep; 21(9):507-12. PubMed ID: 8565438 [TBL] [Abstract][Full Text] [Related]
10. Monoamine abnormalities in the SAPAP3 knockout model of obsessive-compulsive disorder-related behaviour. Wood J; LaPalombara Z; Ahmari SE Philos Trans R Soc Lond B Biol Sci; 2018 Mar; 373(1742):. PubMed ID: 29352023 [TBL] [Abstract][Full Text] [Related]
11. [Pharmacological treatments for obsessive-compulsive disorder and the serotonin-dopamine hypothesis]. Okamoto Y Seishin Shinkeigaku Zasshi; 2011; 113(1):36-44. PubMed ID: 21404630 [TBL] [Abstract][Full Text] [Related]
12. A Systematic Review of Evidence-based Treatment Strategies for Obsessive- compulsive Disorder Resistant to first-line Pharmacotherapy. Albert U; Marazziti D; Di Salvo G; Solia F; Rosso G; Maina G Curr Med Chem; 2018; 25(41):5647-5661. PubMed ID: 29278206 [TBL] [Abstract][Full Text] [Related]
14. Serotonin-norepinephrine reuptake inhibitors in the treatment of obsessive-compulsive disorder: A critical review. Dell'Osso B; Nestadt G; Allen A; Hollander E J Clin Psychiatry; 2006 Apr; 67(4):600-10. PubMed ID: 16669725 [TBL] [Abstract][Full Text] [Related]
15. Pharmacologic management of obsessive-compulsive disorder. Jackson CW; Morton WA; Lydiard RB South Med J; 1994 Mar; 87(3):310-21. PubMed ID: 8134850 [TBL] [Abstract][Full Text] [Related]
16. [Diversity of obsessive-compulsive disorder and pharmacotherapy associated with obsessive-compulsive spectrum disorders]. Nakamae T Seishin Shinkeigaku Zasshi; 2011; 113(10):1016-25. PubMed ID: 22187889 [TBL] [Abstract][Full Text] [Related]
17. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder. Mataix-Cols D; Rauch SL; Manzo PA; Jenike MA; Baer L Am J Psychiatry; 1999 Sep; 156(9):1409-16. PubMed ID: 10484953 [TBL] [Abstract][Full Text] [Related]
18. The pathogenesis and treatment of obsessive-compulsive disorder. Dolberg OT; Iancu I; Sasson Y; Zohar J Clin Neuropharmacol; 1996 Apr; 19(2):129-47. PubMed ID: 8777767 [TBL] [Abstract][Full Text] [Related]
19. OCD: where the serotonin selectivity story begins. Pigott TA J Clin Psychiatry; 1996; 57 Suppl 6():11-20. PubMed ID: 8647793 [TBL] [Abstract][Full Text] [Related]
20. Possible role of neuropeptides in obsessive compulsive disorder. McDougle CJ; Barr LC; Goodman WK; Price LH Psychoneuroendocrinology; 1999 Jan; 24(1):1-24. PubMed ID: 10098217 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]